Opendata, web and dolomites

MyeFattyLiver SIGNED

Unravelling the heterogeneity and functions of hepatic myeloid cells in Non-Alcoholic Fatty Liver Disease

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 MyeFattyLiver project word cloud

Explore the words cloud of the MyeFattyLiver project. It provides you a very rough idea of what is the project "MyeFattyLiver" about.

2030    danger    fatty    hypothesize    hits    individual    dissecting    excessive    hepatic    activation    genetic    understand    sequencing    encompasses    population    disease    steatosis    accumulation    world    heterogeneous    initiating    western    phenotypic    experimental    men    steatohepatitis    rna    cirrhosis    therapeutic    play    progression    non    countries    revolutionised    phagocytes    strategies    progressing    functional    date    multiple    roles    predicted    hepatocellular    clinical    ascribed    immune    mononuclear    group    vivo    dendritic    contradictory    biggest    burden    cell    lipids    subtypes    fat    transplantation    mnp    ensuing    inflammatory    excess    sensing    functions    depending    macrophages    heterogeneity    unclear    cellular    types    liver    unravel    facilitated    contributions    mnps    single    alcoholic    nafld    mice    signals    treatment    cells    carcinoma    nash    myeloid    tools    chronic    technologies    health    thought   

Project "MyeFattyLiver" data sheet

The following table provides information about the project.

Coordinator
VIB 

Organization address
address: RIJVISSCHESTRAAT 120
city: ZWIJNAARDE - GENT
postcode: 9052
website: www.vib.be

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Belgium [BE]
 Total cost 1˙500˙000 €
 EC max contribution 1˙500˙000 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2019-STG
 Funding Scheme ERC-STG
 Starting year 2019
 Duration (year-month-day) from 2019-12-01   to  2024-11-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    VIB BE (ZWIJNAARDE - GENT) coordinator 1˙500˙000.00

Map

 Project objective

Non-alcoholic fatty liver disease (NAFLD) results from accumulation of excessive fat in the liver. It encompasses simple steatosis (fatty liver) progressing through non-alcoholic steatohepatitis (NASH), cirrhosis and hepatocellular carcinoma. It is the most common cause of chronic liver disease in western countries and is predicted to be the main cause of liver transplantation by 2030. As such NAFLD represents a significant clinical burden for which to date, there is no effective treatment. Multiple ‘hits’ are thought to contribute to the progression from steatosis to NASH. One of these ‘hits’ is activation of the immune system and the ensuing inflammatory response. Hepatic myeloid cells, including mononuclear phagocytes (MNPs) are thought to play an essential role in this, sensing excess lipids and other danger signals and initiating immune responses. However, MNPs represent a highly heterogeneous population, including multiple subtypes of dendritic cells and macrophages. To date these have been studied as a group rather than as individual cell types, leading to them being ascribed multiple and often contradictory roles depending on the experimental set up. Thus their specific contributions to NAFLD still remain unclear. I hypothesize that by dissecting the phenotypic and functional heterogeneity of hepatic MNPs, we will be able to unravel their roles in NAFLD and in the progression to NASH. Single cell technologies such as single cell RNA sequencing have revolutionised our ability to understand cellular heterogeneity. In addition, they have facilitated the development of novel genetic tools to study functions of specific cell types in vivo. I aim to use this technology and more specific in vivo tools to understand MNP phenotypic and functional heterogeneity in NAFLD in mice and men. This is essential for the development of novel therapeutic strategies targeting myeloid cells in what is becoming one of the biggest health challenges in the western world.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MYEFATTYLIVER" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "MYEFATTYLIVER" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

NanoMechShape (2019)

Molecular control of actin network architecture and mechanics during cell shape changes

Read More  

NanoPD_P (2020)

High throughput multiplexed trace-analyte screening for diagnostics applications

Read More  

SELECTIONDRIVEN (2019)

Gaining insights into human evolution and disease prevention from adaptive natural selection driven by lethal epidemics

Read More